Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent

miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway

(2011) N. M. Alajez et al.   CANCER RESEARCH

Oncolysis of Prostate Cancers Induced by Vesicular Stomatitis Virus in PTEN Knockout Mice

(2010) M. Moussavi et al.   CANCER RESEARCH

A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers

(2010) Jean-Simon Diallo et al.   MOLECULAR THERAPY

Human Bone Marrow-Derived Mesenchymal Stem Cells for Intravascular Delivery of Oncolytic Adenovirus  24-RGD to Human Gliomas

(2009) R. L. Yong et al.   CANCER RESEARCH

Targeted depletion of BMI1 sensitizes tumor cells to P53-mediated apoptosis in response to radiation therapy

(2009) N M Alajez et al.   CELL DEATH AND DIFFERENTIATION

Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment

(2009) Shanthi Marur et al.   MAYO CLINIC PROCEEDINGS

Efficacy of Systemically Administered Mutant Vesicular Stomatitis Virus (VSV 51) Combined with Radiation for Nasopharyngeal Carcinoma

(2008) N. M. Alajez et al.   CLINICAL CANCER RESEARCH